-- Biocon Surges on $200 Million Payment From Pfizer for Biosimilar Insulin
-- B y   S a m   N a g a r a j a n
-- 2010-10-19T03:55:57Z
-- http://www.bloomberg.com/news/2010-10-19/biocon-surges-after-selling-four-insulin-rights-to-pfizer-for-200-million.html
Biocon Ltd. surged as much as 17.2
percent in Mumbai trading after Pfizer Inc., the world’s biggest
drugmaker, agreed to pay $200 million upfront for rights to the
Indian company’s insulin products to expand its diabetes
offerings in emerging markets. Biocon rose 8.7 percent to 438.30
rupees as of 9:24 a.m. local time. The Indian unit of Pfizer
climbed 2.1 percent to 1,113.10 rupees.  To contact the editor responsible for this story:
Sam Nagarajan at 
 samnagarajan@bloomberg.net  